GMP Downgrades Canopy Growth After Mixed Q3

Canadian cannabis company Canopy Growth Corp CGC reported third-quarter results last week that were highlighted by the first revenue beat in the past four quarters, but a gross margins of 22 percent was the worst seen in three years, according to GMP.

  • Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
  • Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
  • Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.
Share Price: $0.80
Min. Investment: $1,000
Valuation: $3.5B

The Analyst

GMP Securities' Martin Landry downgraded Canopy Growth's Toronto-listed stock from Buy to Hold with a price target lowered from CA$70 ($52.87) to CA$65 ($49.09). 

The Thesis

Canopy Growth's Feb. 14 earnings report includes three near-term concerns that imply that a bullish stance on the stock can no longer be justified, Landry said in a Tuesday downgrade note:  

The company exited the quarter with $22 million of finished goods, which is notably lower than $56 million in the prior quarter, the analyst said. This could impact the company's ability to grow in the near-term and gives competitors an opportunity to "catch up" with superior inventory on hand and capacity expansion plans, he said.

Despite the cannabis sector's very young age, Canopy Growth has yet to fully explain its path toward profitability, Landry said. SG&A expenses have now exceeded revenue for each of the past three quarters, which calls into question the company's timeline for reaching positive EBITDA, he said. Canopy Growth could wind up being the last cannabis company to show positive EBITDA within GMP's entire coverage universe, the analyst said.

Finally, Canopy Growth's valuation factors in expectations for large revenue growth, but the company's sales remain small, Landry said. The company generated just $2.7 million in revenue last quarter, yet the stock is up 72 percent in 2019 alone and 12 percent in the past year, he said.

While this move higher may be justified given the company's leadership role in the global cannabis space, a "pause" is likely to be seen before the next move higher given multiple near-term concerns and challenges, according to GMP.

Price Action

Canopy Growth's NYSE-listed shares were down 2.78 percent at $46.21 at the time of publication Tuesday.

Related Links:

Constellation Brands Made The Right Move With Early Cannabis Investment, Wells Fargo Says

Wall Street's Favorite Cannabis Stock

CGC Logo
CGCCanopy Growth Corp
$1.596.00%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
3.88
Growth
19.54
Quality
Not Available
Value
80.09
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Cannabis is evolving—don’t get left behind!

Curious about what’s next for the industry and how to stay ahead in today’s competitive market?

Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.

Secure your spot now before prices go up—this is where the biggest deals and connections happen!

Get your tickets today!

Comments
Loading...